Riskpilot← Back to searchSign inGet full accessAB bioMérieux
ABActiveOrg 5561156844Förändringens Gata 10Manufacture of other chemical products n.e.c. · NACE 2059Est. 19680 employees
Revenue 2024
SEK 0
EBITDA margin
—
+121% vs 2023
Equity ratio
98.4%
Financial strength
Net profit 2024
SEK 375K
+1342% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 55K | +121% |
| Net profit | SEK 375K | +1342% |
| Total assets | SEK 9M | +3% |
| Equity | SEK 8,8M | +4% |
| Employees | 0 | — |
Legal name
AB bioMérieux
Org number
5561156844
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
5 mars 1968
Share capital
SEK 170 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget har till föremål för sin verksamhet att för egen eller annans räkning bedriva verksamhet avseende utveckling, tillverkning, marknadsföring och diagnostika laboratorie- och fältprodukter, bl. a. för befrämjande av ett rationellt bruk av antibiotika och för bioteknisk forskning och produktion, samt avseende forskning, utvecklingsarbete, konsulterande verksamhet och andra tjänster inom dessa områden, förvärva fast och lös egendom som kan användas i eller har samband med denna verksamhet samt att bedriva därmed förenlig verksamhet.
Address
Förändringens Gata 10
Phone
+4631688490
Email
raphaelle.gousset@biomerieux.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 436 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 5 834 | −259 | −261 | −265 | 55 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 5 834 | −259 | −261 | −265 | 55 |
| Net financials | 1 | — | 58 | 291 | 320 |
| Profit before tax | 5 835 | −260 | −203 | 26 | 375 |
| Tax | −1 249 | −0 | −0 | −0 | −0 |
| Net profit | 4 586 | −260 | −203 | 26 | 375 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19 047 | 8 651 | 8 448 | 8 727 | 8 954 |
| Equity | 18 847 | 8 611 | 8 408 | 8 429 | 8 808 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 200 | 40 | 40 | 298 | 146 |
| Total debt | 200 | 40 | 40 | 298 | 146 |
EBITDA margin
5500000.0%
This company
15.8%
Market median
+34810027% vs market
20202024
Equity ratio
98.4%
This company
38.2%
Market median
+158% vs market
20202024
Return on equity
4.3%
This company
18.4%
Market median
-77% vs market
20202024
Net profit margin
37500000.0%
This company
8.1%
Market median
+462962863% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RG Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
DB Chief Executive Officer | Chief Executive Officer | 2022 |
DF Chief Auditor | Chief Auditor | 2025 |
| Former (4) | ||
AK Authorized Recipient of Service | Authorized Recipient of Service | 2021 – 2022 |
IM Chief Auditor | Chief Auditor | 2022 – 2023 |
MG Chief Auditor | Chief Auditor | 2020 – 2024 |
NC Chief Auditor | Chief Auditor | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Former (5) | ||
| Chairman | 2021 – 2022 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Chairman | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BIOMÉRIEUX SA
AB bioMérieux (this company)Board members of AB bioMérieux also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Katarina Amundsson | Authorized Recipient of Service | 0 companies |
| Inger Margareta Sjöberg | Chief Auditor | 0 companies |
| Raphaelle Gousset | Authorized Recipient of Service | 0 companies |
| Mattias Gustaf Erik Olofson | Chief Auditor | 0 companies |
| Denis Bernard Monnaie | Chief Executive Officer | 0 companies |
| Nina Charlotte Angard | Chief Auditor | 0 companies |
| David Fredrik Lawenius | Chief Auditor | 0 companies |
| Rocio Mendez Aleman | Chairman | 0 companies |
| Pascal Jean D. Waucquez | Chairman | 0 companies |
| Véronique Audrey Martin-Sanchez | Board of Directors | 0 companies |
| Urzula Maria Lesniak | Chairman | 0 companies |
| Vincent Bruno Marciniak | Board of Directors | 0 companies |
| Bertrand Playe | Board of Directors | 0 companies |
| Sandrine Regine Guilaine Flory | Chairman | 0 companies |